Low colonization prevalence of Staphylococcus aureus with reduced vancomycin susceptibility among patients undergoing hemodialysis in the San Francisco Bay area

Clinical Infectious Diseases

Volumn 40, Issue 11, 2005, Pages 1617-1624

  Eguía, José M ^a   Liu, Catherine ^d   Moore, Matthew ^a   Wrone, Elizabeth M ^b   Pont, Joan ^c   Gerberding, Julie L ^a   Chambers, Henry F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Satellite Research   (United States)

^c KAISER PERMANENTE MEDICAL CENTER   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VANCOMYCIN;

ADULT; AGED; ARTICLE; BACTERIAL COLONIZATION; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; DRUG EXPOSURE; DRUG SCREENING; DRUG SENSITIVITY; HEMODIALYSIS; HOSPITALIZATION; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIVARIATE ANALYSIS; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; STAPHYLOCOCCUS AUREUS; STRAIN IDENTIFICATION; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; CARRIER STATE; COHORT STUDIES; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NOSE; PREVALENCE; PROSPECTIVE STUDIES; RENAL DIALYSIS; RISK FACTORS; SAN FRANCISCO; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 19344365679     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/429906     Document Type: Article

References (39)

1. Network of Antimicrobial Resistance in Staphylococcus aureus (NARSA). Glycopeptide resistant staphylococci and glycopeptide intermediate staphylococci. Available at: http://www.narsa.net. Accessed 1 August 2004.
2. Fridkin SK, Hageman J, McDougal LK, et al. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin Infect Dis 2003; 36:429-39.
3. Michigan Department of Community Health. Second Michigan VRSA case. 3 March 2005. Available at: http://www.michigan.gov/documents/ VRSA_Feb05_HAN_118391_7.pdf. Accessed 8 April 2005.
4. Walsh TR, Howe RA. The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus. Annu Rev Microbiol 2002; 56:657-75.
5. Chang S, Sievert DM, Hageman JC, et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003; 348:1342-7.
6. Sieradzki K, Tomasz A. Alterations of cell wall structure and metabolism accompany reduced susceptibility of vancomycin in an isogenic series of clinical isolates of Staphylococcus aureus. J Bacteriol 2003; 185:7103-10.
7. Hussain FM, Boyle-Vavra S, Shete PB, Daum RS. Evidence for a continuum of decreased vancomycin susceptibility in unselected Staphylococcus aureus clinical isolates. J Infect Dis 2002; 186:661-7.
8. Boyle-Vavra S, Labischinski H, Ebert CC, Ehlert K, Daum RS. A spectrum of changes occurs in peptidoglycan composition of glycopeptide-intermediate clinical Staphylococcus aureus isolates. Antimicrob Agents Chemother 2001; 45:280-7.
9. Howe RA, Monk A, Wootton M, Walsh TR, Enright MC. Vancomycin susceptibility within methicillin-resistant Staphylococcus aureus lineages. Emerg Infect Dis 2004; 10:855-7.
10. Walsh TR, Bolmström A, Qwärnström A, et al. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J Clin Microbiol 2001; 39:2439-44.
11. Liu C, Chambers HF. Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob Agents Chemother 2003; 47:3040-5.
12. Hiramatsu K, Aritaka N, Hanaki H, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997; 350:1670-3.
13. Kessler M, Hoen B, Mayeux D, Hestin D, Fontenaille C. Bacteremia in patients on chronic hemodialysis: a multicenter prospective survey. Nephron 1993; 64:95-100.
14. Kluytmans J, van Belkum A, Verbrugh HA. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev 1997; 10:505-20.
15. Nsouli KA, Lazarus M, Schoenbaum SC, Gottlieb MN, Lowrie EG, Shocair M. Bacteremic infection in hemodialysis. Arch Intern Med 1979; 139:1255-8.
16. Amir M, Paul J, Batchelor B, et al. Nasopharyngeal carriage of Staphylococcus aureus and carriage of tetracycline-resistant strains in associated with HIV-seropositivity. Eur J Clin Microbiol Infect Dis 1995; 14:34-40.
17. Meynard JL, Barbut F, Blum L, et al. Risk factors for isolation of Streptococcus pneumoniae with decreased susceptibility to penicillin G from patients infected with human immunodeficiency virus. Clin Infect Dis 1996; 22:437-40.
18. Wood CA. Rifampicin-resistant staphylococcal bacteraemia in patients with AIDS receiving rifabutin [letter]. Lancet 1994; 343:919-20.
19. NCCLS. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. NCCLS document M7-A5. Wayne, PA: NCCLS, 2000.
20. Diekema DJ, Pfaller MA, Schmitz FJ, et al. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001; 32(Suppl 2):S114-32.
21. Geisel R, Schmitz FJ, Thomas L, et al. Emergence of heterogeneous intermediate vancomycin resistance in Staphylococcus aureus isolates in the Dusseldorf area. J Antimicrob Chemother 1999; 43:846-8.
22. Ariza J, Pujol M, Cabo J, et al. Vancomycin in surgical infections due to methidllin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin. Lancet 1999; 353:1587-8.
23. Chesneau O, Morvan A, Solh NE. Retrospective screening for heterogeneous vancomycin resistance in diverse Staphylococcus aureus clones disseminated in French hospitals. J Antimicrob Chemother 2000; 45:887-90.
24. Hageman J, Pegues DA, Jepson C, et al. Vancomycin-intermediate Staphylococcus aureus in a home health-care patient. Emerg Infect Dis 2001; 7:1023-5.
25. Naimi TS, Anderson D, O'Boyle C, et al. Vancomycin-intermediate Staphylococcus aureus with phenotypic susceptibility to methicillin in a patient with recurrent bacteremia. Clin Infect Dis 2003; 36:1609-12.
26. Tokars JI, Miller ER, Stein G. New national surveillance system for hemodialysis-associated infections: initial result. Am J Infect Control 2002; 30:288-95.
27. Green K, Schulman G, Haas DW, Schaffner W, D'Agata EM. Vancomycin prescribing practices in hospitalized chronic hemodialysis patients. Am J Kidney Dis 2000; 35:64-8.
28. Harris AD, Samore MH, Lipsitch M, Kaye KS, Perencevich E, Carmeli Y. Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, enterococci, and Escherichia coli. Clin Infect Dis 2002; 34:1558-63.
29. Schwaber MJ, Wright SB, Carmeli Y, et al. Clinical implications of varying degrees of vancomycin susceptibility in methicillin-resistant Staphylococcus aureus bacteremia. Emerg Infect Dis 2003; 9:657-64.
30. Charles PGP, Ward PB, Johnson PDR, Howden BP, Grayson ML. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis 2004; 38:448-51.
31. Yu VL, Goetz A, Wagener MM, et al. Staphylococcus aureus nasal carriage and infection in patients on hemodialysis. N Engl J Med 1986; 315:91-6.
32. von Eiff C, Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia. N Engl J Med 2001; 344:11-6.
33. Denis O, Nonhoff C, Byl B, Knoop C, Bobin-Dubreux S, Struelens MJ. Emergence of vancomycin-intermediate Staphylococcus aureus in a Belgian hospital: microbiological and clinical features. J Antimicrob Chemother 2002; 50:383-91.
34. Aucken HM, Warner M, Ganner M, et al. Twenty months of screening for glycopeptide-intermediate Staphylococcus aureus. J Antimicrob Chemother 2000; 46:639-40.
35. Moore MR, Perdreau-Remington F, Chambers HF. Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis. Antimicrob Agents Chemother 2003; 47:1262-6.
36. Sieradzki K, Leski T, Dick J, Borio L, Tomasz A. Evolution of a vancomycin-intermediate Staphylococcus aureus strain in vivo: multiple changes in the antibiotic resistance phenotypes of a single lineage of methicillin-resistant S. aureus under the impact of antibiotics administered for chemotherapy. J Clin Microbiol 2003; 41:1687-93.
37. Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-intermediate Staphylococcus aureus Working Group. N Engl J Med 1999; 340:493-501.
38. Enright MC, Robinson DA, Randle G, Feil EJ, Grundmann H, Spratt BJ. The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA). Proc Nat Acad Science USA 2002; 99:7687-92.
39. Sakoulas G, Eliopoulos GM, Moellering RC, et al. Staphylococcus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermediate-level glycopeptide resistance? J Infect Dis 2003; 187:929-38.